LONDON -- The first clinical trial of an entirely new class of cancer drugs has delivered exciting results, including the first indication that it might be able to halt the disease in patients.
The Phase I trial assessed the safety and toxicity of a drug called 17AAG, which inhibits heat-shock protein 90, or HSP90, and found molecular evidence that the drug can inhibit its target in patients' tumors.
Two people with malignant melanoma who took part in the trial entered stable disease, where their tumors failed to progress. Those individuals lived for 15 months and five years while taking 17AAG, although the average life expectancy for people with late-stage malignant …
No comments:
Post a Comment